Omnicell AI Stock Analysis
Want to see OMCL full AI Analyst Report?
Omnicell (OMCL) AI Stock Analysis
Omnicell
(NASDAQ:OMCL)
The score is driven primarily by improving fundamentals (strong free cash flow and reduced leverage) and a positive earnings update with raised profitability guidance. These strengths are tempered by weak and volatile top-line performance, an elevated P/E valuation, and only mixed technical conditions with the stock still below key longer-term moving averages.
Omnicell Key Performance Indicators (KPIs)
Revenue by SegmentShows how revenue is distributed among various business segments, indicating which areas drive growth and where strategic focus might be needed.
Service revenue has been the steadier, faster-growing leg, steadily taking a much larger share of the business and materially improving revenue visibility, while Product revenue remains bigger but far lumpier—peaking then collapsing in 2022–23 before recovering and leveling off more recently. That mix shift de-risks quarter-to-quarter swings and rewards execution on attach rates and renewals, but the company’s near-term upside still depends on sustaining product demand and converting one-time system sales into recurring service relationships.
Omnicell (OMCL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.59B
- Dividend Yield
- ―
- Average Volume (3M)
- 564.97K
- Price to Earnings (P/E)
- 35.6
- Beta (1Y)
- 0.89
- Revenue Growth
- 5.62%
- EPS Growth
- 126.76%
- Country
- US
- Employees
- 3,450
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Omnicell Business Overview & Revenue Model
Company Description
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the heal...
How the Company Makes Money
Omnicell makes money by selling and supporting medication management technology and related services for healthcare providers. Key revenue streams include: (1) Product/Systems revenue: sale of medication management hardware such as automated dispensi...
Omnicell Earnings Call Summary
The call was broadly positive. The company exceeded third-quarter revenue and EBITDA guidance, raised full-year EBITDA and EPS guidance, reported growing and increasingly mature pipeline activity, and highlighted customer validation for Titan XT and OmniSphere. The main challenges were timing variability in back-end-weighted bookings, modest near-term top-line growth, lower fourth-quarter revenue guidance, memory-cost pressure, a modest 340B-related ARR impact, and the multi-year timeline for OmniSphere monetization. The positive operating results, strategic progress, and pipeline commentary significantly outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter of 2026, Omnicell expects total revenue in the range of $295 million-$301 million, non-GAAP EBITDA in the range of $30 million-$36 million, and non-GAAP earnings per share in the range of $0.41-$0.49; for full-year 2026, the company reiterated product bookings in the range of $425 million-$560 million, total revenue in the range of $1.225 billion-$1.231 billion, product revenue in the range of $684 million-$687 million, service revenue in the range of $541 million-$544 million, and year-end 2026 ARR in the range of $660 million-$670 million, while raising non-GAAP EBITDA guidance to the range of $187 million-$193 million and non-GAAP earnings per share guidance to the range of $2.48-$2.56; full-year 2026 bookings are expected to be back-end weighted, the company continues to target the first half of 2027 for general availability of OmniSphere, anticipates a modest impact on its 2026 ARR from the 340B Drug Pricing Program environment, and expects roughly half of the approximately $6 million in incremental second half memory cost in the fourth quarter.
Omnicell Financial Statement Overview
Summary
Overall financial quality is improving, led by strong and improving free cash flow and a meaningfully de-levered balance sheet (low debt-to-equity). Profitability has rebounded, but the sharp TTM revenue decline and multi-year top-line choppiness keep the score below the high range.
Income Statement
56NeutralBalance Sheet
72PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.24B | 1.18B | 1.11B | 1.15B | 1.30B | 1.13B |
| Gross Profit | 561.45M | 508.04M | 471.00M | 499.93M | 588.99M | 554.65M |
| EBITDA | 150.16M | 101.87M | 119.87M | 79.98M | 96.85M | 173.33M |
| Net Income | 44.67M | 2.05M | 12.53M | -20.37M | 5.65M | 77.85M |
Balance Sheet | ||||||
| Total Assets | 2.06B | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 314.86M | 211.17M | 381.68M | 479.84M | 341.85M | 359.72M |
| Total Debt | 200.75M | 204.34M | 382.55M | 614.09M | 616.74M | 541.01M |
| Total Liabilities | 739.58M | 742.91M | 877.65M | 1.04B | 1.08B | 995.81M |
| Stockholders Equity | 1.32B | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B |
Cash Flow | ||||||
| Free Cash Flow | 144.57M | 86.89M | 151.26M | 139.62M | 17.04M | 202.84M |
| Operating Cash Flow | 187.45M | 127.30M | 187.72M | 181.09M | 77.78M | 231.81M |
| Investing Cash Flow | -55.92M | -60.36M | -52.79M | -55.02M | -58.67M | -412.50M |
| Financing Cash Flow | -24.97M | -218.32M | -235.58M | 23.42M | -20.95M | 47.36M |
Omnicell Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Negative. The current price of 34.66 is below the 20-day moving average (MA) of 36.38, below the 50-day MA of 35.11, and below the 200-day MA of 38.16, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 14.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OMCL.
Omnicell Risk Analysis
Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.
Latest Risks Added
3 New RisksOmnicell Peers Comparison
Overall Rating
PHR69Neutral
CCLD66Neutral
OPRX65Neutral
OMCL63Neutral
HCAT54Neutral
DH50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $760.99M | 71.20 | 3.01% | ― | 12.93% | ― | |
| 66Neutral | $101.27M | 18.34 | 24.48% | ― | 14.86% | 214.99% | |
| 65Neutral | $138.21M | 27.73 | 3.84% | ― | -13.98% | 17806.67% | |
| 63Neutral | $1.59B | 35.55 | 3.50% | ― | 5.62% | 126.76% | |
| 54Neutral | $98.24M | -0.46 | -128.24% | ― | -13.88% | -78.38% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $194.65M | -0.89 | -87.69% | ― | -6.18% | 10.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OMCL | Omnicell | 34.66 | 0.34 | 0.99% | |
| OPRX | Optimizerx Corporation | 7.31 | -6.27 | -46.17% | |
| CCLD | Carecloud, Inc. | 2.38 | -0.47 | -16.49% | |
| PHR | Phreesia | 12.26 | -6.79 | -35.64% | |
| HCAT | Health Catalyst | 1.29 | -0.74 | -36.45% | |
| DH | Definitive Healthcare Corp. Class A | 1.34 | -1.26 | -48.46% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
